Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

New Emergence of Potential Tx & Dx Options Predicted to Transform the Current Landscape for Liver Diseases (NASH) to a $35 Billion Opportunity


News provided by

Research and Markets

26 Feb, 2016, 10:10 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

DUBLIN, Feb. 26, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/8kq9f9/new_emergence_of) has announced the addition of the "New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)" report to their offering.

Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years. Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025.

Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year

Key Topics Covered:

1. Conatus Pharmaceuticals (CNAT)

- Emricasan: Disease Modifying Potential Across The Spectrum Of Liver Diseases

- Key Milestones (CNAT)

- Trends In Overall Population Driven By Significant Improvement In Meld =15 Subgroup - Figure 1 Conatus Pharma

- Emricasan: Data From PhII, Liver Cirrhosis Trial (3-Month - Table 1 Conatus Pharma

- PhIIb, Encore Program In Different Etiologies & Stages - Table 2 Conatus Pharma

- Competitive Landscape (Late-Stage Pipeline) For Nash - Figure 2 Conatus Pharma

- Emricasan: Medical Need And Market Opportunities - Figure 3 Conatus Pharma

- Emricasan: A Potent Inhibitor Of Apoptotic And Inflammatory Caspases - Figure 4 Conatus Pharma

- Emricasan: Phase II, Liver Cirrhosis Trial (3 Months) - Figure 5 Conatus Pharma

- Emricasan: Phase II Data @ Easl, 2015 - Figure 6 Conatus Pharma

- Emricasan: Phase II Data @ Aasld, 2015

- Changes In Clinical, Biochemical, And Biomarker Parameter From Baseline

2. Galectin Therapeutics (GALT) - Reversing Late-Stage Nash (Advanced Fibrosis) -Key Milestones (GALT) - Competitive Landscape (Late-Stage Pipeline) For Nash - Role Of Galectin-3 In Pathophysiology Of Nash And Fibrogenesis - Phase II Trial Designs: Nash-Cx (W/ Cirrhosis) & Nash-Fx (W/ Advanced Fibrosis) - Gr-Md-02: Phi Study - Serum Biomarkers Evaluation - Figure 4 Galectin Therapeutics - Gr-Md-02: Preclinical Data - TX Effect On Nash With Fibrosis - Figure 5 Galectin Therapeutics - Pipeline Portfolio

3. Galmed Pharmaceuticals (GLMD)-Aramchol: A Differentiated Approach, Targeting Early Nash And Potentially, NAFL PTS

- Key Milestones (GLMD) - Table 1 Galmed Pharmaceuticals

- Competitive Landscape (Late-Stage Pipeline) For Nash - Figure 1 Galmed Pharmaceuticals

- Aramchol: Phase IIa Data - Relative Change In Liver-Fat Concentration - Figure 2 Galmed Pharmaceuticals

- Aramchol: Differentiated Mode Of Action - Figure 3 Galmed Pharmaceuticals

- Aramchol: Clinical Trials And Its Endpoints - Figure 4 Galmed Pharmaceuticals

- Phase II Results: Changes In Cholesterol And Serum Adiponectin Levels - Figure 5 Galmed Pharmaceuticals

- Changes In The Levels Of Cholesterol Crystallization After The Addition Of Aramchol

4. Genfit Sa (Gnft) - Gnft Offers Remarkable Nash Treatment Package: Robust Drug + Non-Invasive Biomarker Test - Key Milestones (Gnft) - Figure 1 Genfit Sa - Golden-505: Comparison With Other PhII Studies - Figure 2 Genfit Sa - Golden-505: Comparison With Other PhII Studies - Table 1 Genfit Sa - Competitive Landscape (Late-Stage Pipeline) For Nash - Table 1 Genfit Sa - Part 2 - Competitive Landscape (Late-Stage Pipeline) For Nash - Figure 3 Genfit Sa - Elafibranor: Ppar Regulates Numerous Pathways Essential In Nash - Clinical Development -Figure 4 Genfit Sa - Elafibranor: Phase III Trial Design - Figure 5A Genfit Sa - Golden-505: Improvement In Cardio-Metabolic And Glycemic Parameters - Figure 6 Genfit Sa - Efficacy Of Gft505 In Animal Models Of Nafld/ Nash And Liver Fibrosis - Figure 7 Genfit Sa - Efficacy Of Gft505 In Animal Models Of Nafld/ Nash And Liver Fibrosis - Figure 8 Genfit Sa - Effects Of Gft505 In Rats With Established Hepatic Fibrosis - Figure 8 Genfit Sa - Effects Of Gft505 In Rats With Established Hepatic Fibrosis

5. Intercept Pharmaceuticals (ICPT)

- Mixed Data And Pricing/Reimbursement Concerns May Limit Oca'S Market Potential - Figure 1 Intercept Pharmaceuticals

- Global Pbc Patient Waterfall

- Key Milestones (ICPT) - Figure 2 Intercept Pharmaceuticals

- Flint Study Results: Improvement In Nas, Fibrosis, And Nash Resolution - Table 1 Intercept Pharmaceuticals

- Competitive Landscape (Late-Stage Pipeline) For Nash - Figure 3 Intercept Pharmaceuticals

- FXR Is Central To A Multitude Of Pathways - Figure 5 Intercept Pharmaceuticals

- Poise Study: Met The Primary Endpoint As Early As 2 Weeks - Figure 6

6. Intercept Pharmaceuticals - Flint Study: Response Rates, Fibrosis Improvemen - Key Milestones - Figure 1 Tobira Therapeutics - Centaur - PhIIb Clinical Trial Vs. Other Published PhIIb Studies In Nash (TBRA) - Tobira Therapeutics - Cenicriviroc (CVC): A Potent Inhibitor Of Infiltration Of Pro-Inflammatory Monocytes - Obira Therapeutics - Drugs In Development For Nash

Companies Mentioned

- Conatus Pharmaceuticals (CNAT) - Galectin Therapeutics (GALT) - Galmed Pharmaceuticals (GLMD) - Genfit SA (GNFT) - Intercept Pharmaceuticals (ICPT) - Tobira Therapeutics (TBRA)

For more information visit http://www.researchandmarkets.com/research/8kq9f9/new_emergence_of

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


 

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.